Table 5.
Summary of clinical studies that have evaluated the efficacy of aflibercept for treating non-responders to other anti-VEGF therapies
| Study | Design | Size | Preswitch treatment | Preswitch mean number of injections | Mean follow-up post-switch | Postswitch mean number of injections | Visual acuity following switch | Anatomic measures of response |
|---|---|---|---|---|---|---|---|---|
| 195 | Retrospective | 102 eyes | RBZ, Bev, both | 20.4 | 18 weeks | 3.8 | Stable | Decreased CMT, intraretinal, and subretinal fluid |
| 296 | Retrospective | 36 eyes | RBZ, Bev, both | 25.6 | 6 months | 3 or more | Stable | Decrease in CMT |
| 397 | Retrospective | 96 eyes | RBZ, Bev, both | 17 | 114 days | 2.6 | Stable | Decrease in macular cube volume |
| 498 | Retrospective | 34 eyes | RBZ, Bev, both | 28.6±20.1 | 6.5±0.5 months | 5.3±0.6 | Improved | Decrease in central foveal thickness, PED height, and diameter |
| 599 | Retrospective | 266 eyes | RBZ, Bev, both | 14.7 | 12 months | >5 | Stable | Decrease in central subfoveal thickness |
| 6100 | Prospective | 49 eyes | RBZ, Bev, both | 34.9±16.1 | 24 months | N/A | Improved | Decrease in central retinal thickness |
| 7101 | Retrospective | 31 eyes | RBZ or both | 34.4±11.9 | 6 months | 4.5 | Stable | Decreased central subfield thickness, PED height, subfoveal choroidal thickness, intraretinal fluid, and subretinal fluid |
| 8102 | Retrospective | 47 eyes | RBZ or both | 11.3±5.96 | N/A | 3 | Stable | Decreased central retinal thickness and retinal fluid volume |
| 9103 | Prospective | 49 eyes | RBZ, Bev, both | 34.9±16.1 | 48 weeks | 8 | Stable | Decrease in PED dimensions |
| 10104 | Retrospective | 3 eyes | RBZ or both | 5±1.5 | 3 months | 3 | Improved (not statistically tested) | Decrease in PED height |
| 11105 | Retrospective | 21 eyes | RBZ, Bev, both | 29.8±17.1 | 12 months | 10.2±1.2 | Stable | Decrease in central foveal thickness, subretinal fluid, macula volume, and PED dimensions |
Notes: Note the marked heterogeneity in sample size, treatment regimens (before and after aflibercept switch) and duration of follow-up between studies. Data presented as mean ± standard deviation.
Abbreviations: RBZ, ranibizumab; Bev, bevacizumab; both, ranibizumab and bevacizumab; N/A, not available; CMT, central macular thickness; PED, pigment epithelial detachment.